Lung Cancer in Practice

This item requires a subscription.

The place of erlotinib in the NHS following NICE’s final guidance
LCIP, Volume 5, Number 3.

n recent times, through a study of the signalling pathways involved in cancer development, growth and spread, we have passed a number of important milestones in our understanding of cancer. Since the turn of the century, a number of inhibitors of these pathways have been developed and tested. Some of these products have proved a success and have already found their way into clinical practice.

To view this item, select one of the options below:

	Purchase access
	In order to view articles you will need to pay a subscription for either 24-hour or annual access. You can view all articles on this site during the subscription period. Please click here to subscribe.

	Sign in
	If you are already have a subscription, please sign in here.
	email address
	Password
	Forgotten your password?

	Important
	All the articles are in PDF format.
	To view the articles you will need Adobe Acrobat Reader.
	To download a copy, free of charge, please click here.

	Help
	If you need help accessing this site, please click here.

The data, opinions and statements appearing in the articles herein are those of the contributor(s) concerned; they are not necessarily endorsed by the sponsors, publisher, Editor or Editorial Board. Accordingly the sponsors, publisher, Editor and Editorial Board and their respective employees, officers and agents accept no liability for the consequences of any such inaccurate or misleading data, opinion or statement.
Copyright (©) 2010 Hayward Group Ltd. The title Lung Cancer in Practice is the property of Hayward Group Ltd and, together with the content, is bound by copyright. The information contained on the site may not be reproduced, distributed or published, in whole or in part, in any form without the permission of the publishers. All correspondence should be addressed to: admin@hayward.co.uk